‘As millions of Americans continue to open to the many benefits of Cannabis, Medical Marijuana is showing it’s true colors. From this one amazing plant people and animals of all shapes and sizes are experiencing greater wellness on many levels.
Beyond all the hype of this God given, life providing plant, you can be sure that Cannabis has something for every ‘body’ in its raw natural form. Beyond the separation of terpenes is the full spectrum cannabis plant with all the cannabinoids for whole health and wellness!’. ‘This is my findings as I continue to research the benefits of cannabis for HempingtonPost and all our amazing readers and Cannabis/Hemp enthusiasts and seekers of truth above all!
I found this backup of researched info on the many benefits of Cannabis from MedWeb below’ From the editor, Darlene Mea, CEO, Founder HempingtonPost.
Please enjoy and share this info – Full Spectrum Cannabis is for every ‘body’
More than half of U.S. states and the District of Columbia have legalized medical marijuana in some form, and more are considering bills to do the same. Yet while many people are using marijuana, the FDA has only approved it for treatment of two rare and severe forms of epilepsy, Dravet syndrome and Lennox-Gastaut syndrome.
Why hasn’t more research been done? One reason is that the U.S. Drug Enforcement Administration (DEA) considers marijuana a Schedule I drug, the same as heroin, LSD, and ecstasy, and likely to be abused and lacking in medical value. Because of that, researchers need a special license to study it, says Marcel Bonn-Miller, PhD, a substance abuse specialist at the University of Pennsylvania Perelman School of Medicine.
That may not change anytime soon. The DEA considered reclassifying marijuana as a Schedule II drug like Ritalin or oxycodone, but decided ito keep it as a Schedule I drug.
The agency did, however, agree to support additional research on marijuana and make the process easier for researchers.”Research is critically needed, because we have to be able to advise patients and doctors on the safe and effective use of cannabis,” Bonn-Miller says.
He shared some background on medical marijuana’s uses and potential side effects.
What is medical marijuana?
Medical marijuana uses the marijuana plant or chemicals in it to treat diseases or conditions. It’s basically the same product as recreational marijuana, but it’s taken for medical purposes.
The marijuana plant contains more than 100 different chemicals called cannabinoids. Each one has a different effect on the body. Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the main chemicals used in medicine. THC also produces the “high” people feel when they smoke marijuana or eat foods containing it.
But it’s not yet proven to help many of these conditions, with a few exceptions, Bonn-Miller says.
“The greatest amount of evidence for the therapeutic effects of cannabis relate to its ability to reduce chronic pain, nausea and vomiting due to chemotherapy, and spasticity [tight or stiff muscles] from MS,” Bonn-Miller says.
How does it help?
Cannabinoids — the active chemicals in medical marijuana — are similar to chemicals the body makes that are involved in appetite, memory, movement, and pain.
Despite its official stance, the American government has been quietly financing cannabis research in Israel for decades. More recently, funding was taken over by Big Pharma. You just can’t make this up.
From the CEO of HempingtonPost – Darlene Mea – ‘I’m re’sharing this post now from RXLEAF the weekend of US Independence for Freedom. We the People need to share Truth Above All. While the US imprisoned millions over the past 77 years for cannabis aka Weed, the devils drug – they’ve also fully supported research for cannabis medicine in Israel for the past 50 years – How corrupt the US is to their people who are still dying to be freed from pain and suffering and imprisonment .
It’s time to know the truth and do something about the truth. Vote Consciously! Take the time to reach out to your state representatives and demand full legalization of Cannabis, marijuana and Hemp! If we the people don’t make the moves to gain our rights back, it will NOT be done for us…this is very apparent!’
Although the federal government maintains that cannabis is a schedule I narcotic with no medicinal benefit, U.S. tax dollars (and many more private dollars) have been bankrolling medical cannabis research for years. Except not on American soil, in Israel.
If that sounds like pure hypocrisy, it definitely is.
But it’s also may be one of the smartest moves the United States has made in regards to cannabis policy (as depressing as that is). Despite the acknowledged position of the American Medical Association and a great many pro-cannabis states, politicians at the federal level are still wary of openly advocating for research into cannabis.
So instead of buckling down and doing the hard work, America opened its regular playbook and decided to pay foreigners to do the work it doesn’t want to do itself.
It All Started With One Worried Parent
Back in the 1960s, Israel was one of three countries in the world with a government-sponsored cannabis program. And it was 1963 when an eager, cannabis-passionate Israeli researcher at Hebrew University sought a grant from the NIH. He was originally turned down because “marijuana was not an American problem.”
(It is interesting to note that this young researcher was none other than Raphael Mechoulam, who would go on to be lauded as the ‘Father of Cannabis.’)
One year after Mechoulam’s request, a United States senator caught his son using ‘drugs’ and called the young researcher back. The distraught senator promised to fund any work if Mechoulam could explain what cannabis might be doing to his boy’s brain. It seems that the U.S. had no data on this, which was ultimately an embarrassment for the NIH.
So begins half a century of funding medical research into a narcotic with no medicinal value.
Cannabis Has No Medicinal Value?
Thus, the U.S. National Institutes of Health got involved in the cannabis research business. A world of shady financing deals was born. Mechoulam and his team were given $100,000 every year for the next 50 so that they could continue research into cannabis medicine.
(Side note: no one has ever released the name of the senator who bravely chose to ignore a significant public health issue until it happened in his own home. It’s a shame, too, because he may have done as much for sick Americans as any politician in history.)
Why Don’t They Fund American Cannabis Research?
One caveat: the US does allow some American cannabis research to take place within its borders. Approval is just very, very unlikely. If you’re a willing and able researcher hoping to unlock cannabis’ potential to treat cancer, for example, you’ll need to get approval from the Food and Drug Administration, the Drug Enforcement Agency, and the National Institute on Drug Abuse. And that’s just from the Feds.
You’ll also have to go through the usual research processes, such as institutional review boards, funding sources, etc. as well. Then, if you finally secure enough signatures to begin research, you can only conduct your work using cannabis from one farm. This happens to be located at the University of Mississippi and is overseen by the National Institute on Drug Abuse. In the end, it’s probably just easier to move to Canada.
Still, the threat of a U.S. public embracing a “dangerous plant” is edging ever closer to a national tipping point. It’s getting very difficult to dismiss the videos and personal accounts of real, life-saving work. The peer-reviewed research is piling up, and we are ever closer to human trials on many accounts.
Still, it’s nauseating that Big Pharma is playing both sides. In the short term, its maximizing profits on opioids and other pain relievers in the profit-hungry American medical market. In the long term, it’s working to gain a foothold in the latest frontiers of cannabis research. Sure, that’s a two-faced way to approach things, but it keeps the right pockets lined. That’s what it’s always been about anyway, right?
A December 2019 Nielsen study found pet owners are looking to CBD to help their four-legged companions with:
Back and joint pain.
Episodic and chronic anxiety.
General health and wellness.
Luke Mullins, vice president of sales at Mary’s Tails, told Hemp Industry Daily that the company is in 1,000 retailers nationally, with plans to double that by year’s end.
Mullins notes that Mary’s Tails is careful about how they describe their products to avoid the warning letters the FDA has sent to “unscrupulous operators” that make claims that are not scientifically proven.
“We believe that our tagline – keeping your pets happy, healthy and calm – is a great summation of our products’ benefits,” Mullins said, adding that that they are mindful of the parameters federal agencies have set.
“So while we believe in the value and efficacy of all of our products, we are not permitted to speak to those concepts,” he said.
Education is key
Despite the increase, there’s still a lack of knowledge from consumers about CBD for their pets and how to use it properly, Lange said.
“A lot of people don’t know that pets and humans or dogs and humans share the same endocannabinoid system,” she said. “I think a lot of people think of CBD as cannabis, thinking probably it could make their dog high.”
Gordon, from Functional Remedies, said veterinary clinics have been instrumental about educating the public.
“I think that is really where we’re seeing a turn from,” he said. “Yes, you can go buy them in retail, but you can also go buy them now from a trusted source, and that being your veterinarian who also wants these products on the shelf as well.”
In fact, Nielsen surveyed 100 veterinarians in April and found that they have a greater awareness than physicians about CBD, “at an incidence double that of physicians,” Lange said.
The FDA hasn’t given veterinarians the go-ahead to sell CBD, but it appears some are doing it anyway, although it’s unclear how many.The American Veterinary Medical Association asked for guidance from the FDA on whether cannabinoids can be safely given to pets and farm animals during an agency hearing last May.“The FDA should clearly articulate where various cannabis-derived products fall,” Dr. Ashley Morgan said.Morgan inadvertently got the whole 500-seat room laughing when an FDA panelist asked if veterinarians are giving pet owners CBD. “No,” Morgan said. After a long pause, she added, “Not legally.”
Gordon said he uses CBD on his own pets.
“I want to give them the ultimate care, just like my own children,” he said.
Kovalchuk’s husband, Igor, suggested cannabis could reduce the virus’ entry points by up to 70 percent. “Therefore, you have more chance to fight it,” he told CTV.
“Our work could have a huge influence — there aren’t many drugs that have the potential of reducing infection by 70 to 80 percent,” he told the Calgary Herald.
While they stressed that more research was needed, the study gave hope that the cannabis, if proven to modulate the enzyme, “may prove a plausible strategy for decreasing disease susceptibility” as well as “become a useful and safe addition to the treatment of COVID-19 as an adjunct therapy.”
Cannabis could even be used to “develop easy-to-use preventative treatments in the form of mouthwash and throat gargle products,” the study suggested, with a “potential to decrease viral entry” through the mouth.
“The key thing is not that any cannabis you would pick up at the store will do the trick,” Olga told CTV, with the study suggesting just a handful of more than 800 varieties of sativa seemed to help.
All were high in anti-inflammatory CBD — but low in THC, the part that produces the cannabis high.
The study, which has yet to be peer-reviewed, was carried out in partnership with Pathway Rx, a cannabis therapy research company, and Swysh Inc., a cannabinoid-based research company.
The researchers are seeking funding to continue their efforts to support scientific initiatives to address COVID-19.
“While our most effective extracts require further large-scale validation, our study is crucial for the future analysis of the effects of medical cannabis on COVID-19,” the research said.
“Given the current dire and rapidly evolving epidemiological situation, every possible therapeutic opportunity and avenue must be considered.”
Editor’s note: ‘Please note, full spectrum Cannabis with THC can be even more powerful for deep balancing of our endocannabinoid system which balances the endocrine system while reigniting our immune system. Cannabis has been used for thousands of years as the go to herb throughout the world. It has been less than 100 years since Cannabis became demonized and outlawed by those who rule with greed and power!’ states Darlene Mea CEO & Founder of HemingtonPost.com
NEW YORK, May 7, 2020 /PRNewswire/ FinancialBuzz.com News Commentary
Any time we see the power of psilocybin being brought to the forefront of life, I am personally very delighted ! I am a ‘whole plant healing’ researcher and I know the benefits of both psilocybin and cannabis. So the fact that the FDA is looking means we are taking leaps and bounds in this promising future of the magic in mushroom and cannabis! Life is unfolding in some areas of reality in amazing ways, for this we can be grateful… If you’re not familiar with the powerful effects of psilocybin on our Mind Body and Spirit watch Fantastic Fungi!
Data indicates that psychedelics are gaining popularity. For example, in 2019, the Global Drug Survey collaborated with psychedelic researchers to examine the acceptability of psychedelic products and other drugs such as MDMA (ecstasy) and ketamine in the field of psychiatry. “We found high rates of acceptance especially among those with prior experience of using them, although fears based on myths and outdated science, were evident among psychedelic-naïve respondents,” the survey conclusion shows. Just earlier last year the U.S. Food and Drug Administration (FDA) approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression). Now as states begin to mull the question of psilocybin’s legality, this new field of potential medicinal substances may follow a comparable pathway to legalization with the cannabis medical market.
The growing awareness of cannabidiol, or CBD’s, health benefits has pushed the market into mainstream retail. And yet, despite its growth of recent years, it is important to remember that cannabis products are still illegal in the U.S on the federal level. This regulatory hurdle is one of the last remaining obstacles that has been holding the industry back to a certain degree. “There is plenty of room for growth here,” believes Confident Cannabis VP of Growth & Marketing Brad Bogus according to a report by Civilized. “CBD is sort of stuck in between prohibition era policies and federal acceptance. We just saw the first cannabis derived FDA approved medication make its way onto the market, which is a CBD medication. Where it goes from here in the world of Big Pharma is hard to say, but the direction will be up, in some velocity. Seniors are more keen to try a CBD product over a THC product, so even on the regular non-pharmaceutical market, CBD will still snag a good portion of untapped market share. International trade of source material is another big advantage of the CBD market, to help it grow.”